Literature DB >> 9266665

Aspects of the pharmacokinetics of doxycycline given to healthy and pneumonic East African dwarf goats by intramuscular injection.

I M Ole-Mapenay1, E S Mitema, T E Maitho.   

Abstract

The effect of experimentally induced Pasteurella haemolytica pneumonia on the pharmacokinetics of doxycycline (Doxycen Retard) administered intramuscularly was studied in seven East African dwarf goats. The study was conducted in two consecutive phases, separated by a washout period of four weeks. The experimental infection, induced by intratracheal administration of 5 ml of 10(7) to 10(9) cfu/ml of Pasteurella haemolytica, produced a temperature rise, depression and laboured breathing within 6-12 days after inoculation. The concentrations of doxycycline in the serum were determined by a quantitative microbiological assay using an agar-gel diffusion method employing Bacillus cereus var mycoides (ATCC 11778) as the test organism, with a level of detectability of approximately 0.05 micrograms/ml. The concentration-time curve of doxycycline in the serum after intramuscular injection of 20 mg/kg bodyweight of the long-acting formulation before and after experimental infection was adequately described by a one-compartment open model. The maximum serum concentrations (Cmax) of doxycycline were lower in pneumonic goats than in healthy goats (3.87 +/- 0.52 and 5.56 +/- 0.213 micrograms/ml, respectively), suggesting an increased distribution volume in the peripheral compartment. The mean +/- SEM absorption rate (ka) before infection (1.13 +/- 0.02 h-1) was smaller than the after infection (8.23 +/- 3.81 h-1), but the difference was not significant. The apparent elimination half-life (t 1/2 beta) (24.51 +/- 0.02 h) after infection was significantly increased (p < 0.05), while the corresponding rate constant (beta) was decreased (p < 0.01). The absorption half-life (t 1/2(alpha)) (0.137 +/- 0.03 h) was significantly decreased (p < 0.01) after infection. The distribution volume (Vd(beta)) was significantly increased after infection (p < 0.05). It is concluded that, although experimental infection had an effect on the disposition kinetics of doxycycline, this was not sufficiently pronounced to require alteration of the dosage during disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266665     DOI: 10.1023/a:1005863520483

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  22 in total

1.  The pharmacokinetics of oxytetracycline following intravenous administration in healthy and diseased pigs.

Authors:  A Pijpers; E J Schoevers; H van Gogh; L A van Leengoed; I J Visser; A S van Miert; J H Verheijden
Journal:  J Vet Pharmacol Ther       Date:  1990-09       Impact factor: 1.786

2.  Pharmacokinetic data on doxycycline and its distribution in different biological fluids in female goats.

Authors:  V K Jha; C Jayachandran; M K Singh; S D Singh
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

3.  JANA: a new iterative polyexponential curve stripping program.

Authors:  A Dunne
Journal:  Comput Methods Programs Biomed       Date:  1985-08       Impact factor: 5.428

4.  In vitro activity of five tetracyclines and some other antimicrobial agents against four porcine respiratory tract pathogens.

Authors:  A Pijpers; B Van Klingeren; E J Schoevers; J H Verheijden; A S Van Miert
Journal:  J Vet Pharmacol Ther       Date:  1989-09       Impact factor: 1.786

5.  Relative efficacy of two oxytetracycline formulations and doxycycline in the treatment of acute anaplasmosis in splenectomized calves.

Authors:  K L Kuttler; J E Simpson
Journal:  Am J Vet Res       Date:  1978-02       Impact factor: 1.156

6.  Fever and associated clinical haematologic and blood biochemical changes in the goat and other animal species.

Authors:  A S J P A M van Miert
Journal:  Vet Q       Date:  1985-07       Impact factor: 3.320

Review 7.  Doxycycline.

Authors:  B A Cunha; C M Sibley; A M Ristuccia
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

8.  Some pharmacokinetic data of aditoprim and trimethoprim in healthy and tick-borne fever infected dwarf goats.

Authors:  N W Knoppert; S M Nijmeijer; C T van Duin; C Korstanje; H van Gogh; A S van Miert
Journal:  J Vet Pharmacol Ther       Date:  1988-06       Impact factor: 1.786

9.  Oxytetracycline concentrations in healthy and diseased calves.

Authors:  T R Ames; V L Larson; C M Stowe
Journal:  Am J Vet Res       Date:  1983-07       Impact factor: 1.156

10.  Chloramphenicol, lincomycin and oxytetracycline disposition in calves with experimental pneumonic pasteurellosis.

Authors:  G E Burrows; P B Barto; B R Weeks
Journal:  J Vet Pharmacol Ther       Date:  1986-06       Impact factor: 1.786

View more
  5 in total

1.  The pharmacokinetics of a long-acting oxytetracycline formulation in healthy dogs and in dogs infected with Ehrlichia canis.

Authors:  G M Kikuvi; E S Mitema; I B Buoro
Journal:  Vet Res Commun       Date:  2001-07       Impact factor: 2.459

2.  Evaluation of a Pasteurella multocida Respiratory Disease Induction Model for Goats (Capra aegagrus hircus).

Authors:  Joe S Smith; Jonathan P Mochel; Yeon-Jung Seo; Amanda P Ahrens; Ronald W Griffith
Journal:  Comp Med       Date:  2020-09-09       Impact factor: 0.982

3.  Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs.

Authors:  Lilia Gutiérrez; Zazil-Ha Velasco; Carlos Vázquez; Dinorah Vargas; Héctor Sumano
Journal:  Acta Vet Scand       Date:  2012-06-08       Impact factor: 1.695

4.  Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates.

Authors:  Ehab A Abu-Basha; Nasir M Idkaidek; Tareq M Hantash
Journal:  J Vet Sci       Date:  2006-12       Impact factor: 1.672

5.  Effects of Single and Repeated Doses on Disposition and Kinetics of Doxycycline Hyclate in Goats.

Authors:  Erdinc Turk; Orhan Corum; Ibrahim Ozan Tekeli; Fatih Sakin; Kamil Uney
Journal:  Animals (Basel)       Date:  2020-06-24       Impact factor: 2.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.